A multinational phase 3, randomized, open-label, parallel group study to evaluate the safety and efficacy of relugolix in men with advanced prostate cancer (HERO)

UCI-17-48
NCT03085095
Cancer - Prostate
Edward Uchio
Open
Treatment
Relugolix
3
Adult
Local

For information about cancer clinical trials at the UCI Health Chao Family Comprehensive Cancer Center, call toll-free 877-UC-STUDY (877-827-8839) or email ucstudy@uci.edu.